```text
Wiki Article
Abciximab (C7E3, 143653-53-6): A Research Reagent Overview
Abciximab, also identified as C7E3 or bearing the CAS number 143653-53-6, represents a valuable scientific compound extensively employed in cardiovascular research . This antibody fragment selectively targets the glycoprotein IIb/IIIa complex on blood cells, blocking clot formation . Therefore , it's often investigated as a method to copyrightine the processes underlying thrombosis and to assess the efficacy of anticoagulant therapies. Availability is typically controlled to academic settings.
```
Abciximab Research: Utilizing C7E3 Antibody and 143653-53-6 in Studies
Ongoing investigation into abciximab, a GPIIb/IIIa, frequently utilizes the monoclonal protein C7E3 and the molecule identified as 143653-53-6. These reagents are essential for analyzing abciximab's mode of function, evaluating its efficacy in various clinical settings, and exploring potential indicators of therapeutic success. Continued exploration leveraging these particular reagents is likely to provide valuable information for enhancing clinical applications involving cardiovascular disease.
```text
C7E3 abciximab, also known as c7e3fragment, is a GPIIb/IIIa receptor antagonist widely utilized in scientific research. Its primary application lies in platelet aggregation studies, allowing investigators to probe the mechanisms underlying thrombosis and hemostasis. Researchers employ this agent to investigate the role of platelet activation in various disease models, including ischemia-reperfusion injury and inflammation. Beyond basic research, abciximab is increasingly used in developing novel antithrombotic therapies and evaluating their efficacy. Furthermore, studies exploring its potential to modulate vascular smooth muscle cell function and reduce intracranial bleeding are ongoing. The availability of c7e3 abciximab facilitates a deeper understanding of platelet-mediated processes and contributes to the advancement of translational medicine. }
```
```text
Exploring Potential Opportunities with this Glycoprotein IIb/IIIa Inhibitor 143653-53-6 via C7E3
Recent research demonstrate that Abciximab (identified as 143653-53-6) presents significant scientific potential, particularly when paired with a C7E3 construct. Preliminary findings suggested that this pairing could enhance therapeutic outcomes in several arterial settings. Further investigation is centered on elucidating the precise process of action between Abciximab and C7E3, including assessment of platelet aggregation and vascular safeguarding.
- Future research endeavors intend to refine dosing strategies.
- Animal approaches are are being applied to additional validate the theories.
- Patient trials are essential to completely evaluate therapeutic efficacy.
```
Abciximab (C7E3) for Research: Specifications and Specifications (143653-53-6)
Researchers requiring C7E3 for in vitro studies should meticulously assess integrity and defined specifications . This product is typically provided as a freeze-dried powder and thorough analytical documentation including assessment by mass spectrometry , potency assays, and bacterial endotoxin testing must be available. Verify the supplier's CoA outlines acceptable limits for impurities and conforms to all quality control criteria .
Pharmaceutical-Grade ReoPro Details & Stock
Acquiring research-grade Abciximab, specifically referencing the molecule C7E3 and identified by the chemical number 143653-53-6, requires careful consideration of its manufacturer. This antibody is frequently utilized in laboratory experiments, particularly those related to platelet clumping and thrombosis . Available sources offer this substance in varying volumes, typically ranging from mg to larger wholesale amounts . Kindly advise reviewing the 143653-53-6 report of testing to verify quality and suitability for your specific application . Moreover, check the shelf life date before purchasing to maintain maximum efficacy .
- Common Purity: >95%
- Storage Conditions: -20°C or controlled conditions
- Intended Purpose: Platelet Clumping Suppression Studies